Pharmacy Times July 29, 2024
Providing immunization coadministration and assisting with insurance coverage are strategies to improve access.
May 2023 marked the approval of the first 2 respiratory syncytial virus (RSV) vaccines for adults 60 years and older: Abrysvo (Pfizer Inc) and Arexvy (GSK).1 On May 31, 2024, the FDA approved mRNA-1345 (mRESVIA; Moderna) for the protection of adults 0 years and older against lower respiratory tract disease caused by RSV.2
On June 26, 2024, the CDC updated their RSV recommendations for older adults. Instead of shared clinical decision-making, the CDC now recommends everyone 75 years and older receive 1 RSV vaccine. Individuals 60 to 74 years of age with certain medical conditions, such as cardiovascular disease, or those who reside in a long-term care...
Today's Sponsors
Today's Sponsor